Patents Assigned to IO Biotech ApS
-
Patent number: 11878053Abstract: The invention relates to prophylaxis and therapy of cancer. In particular there is provided a protein Tryptophan 2,3-dioxygenase (TDO) or peptide fragments here of that are capable of eliciting anti-cancer immune responses. Specifically, the invention relates to the use of TDO or peptides derived thereof or TDO specific T-cells for treatment of cancer. The invention thus relates to an anti-cancer vaccine which optionally may be used in combination with other immunotherapies and to TDO specific T-cells adoptively transferred or induced in vivo by vaccination as a treatment of cancer. It is an aspect of the invention that the medicaments herein provided may be used in combination with cancer chemotherapy treatment. A further aspect relates to the prophylaxis and therapy of infections by the same means as described above.Type: GrantFiled: July 7, 2020Date of Patent: January 23, 2024Assignee: IO Biotech ApSInventor: Mads Hald Andersen
-
Patent number: 11648302Abstract: The present invention relates to the field of prophylaxis and therapy of cancer. In particular there is provided a protein Indoleamine 2,3-dioxygenase (IDO) or peptide fragments here of that are capable of eliciting anti-cancer immune responses. Specifically, the invention relates to the use of IDO or peptides derived here from or IDO specific T-cells for treatment of cancer. The invention thus relates to an anti-cancer vaccine which optionally may be used in combination with other immunotherapies and to IDO specific T-cells adoptively transferred or induced in vivo by vaccination as a treatment of cancer. It is an aspect of the invention that the medicaments herein provided may be used in combination with cancer chemotherapy treatment. A further aspect relates to the prophylaxis and therapy of infections by the same means as described above. The use of IDO and immunogenic peptide fragments hereof in cancer and infection treatment, diagnosis and prognosis is also provided.Type: GrantFiled: April 15, 2022Date of Patent: May 16, 2023Assignee: IO BIOTECH APSInventors: Mads Hald Andersen, Per Thor Straten
-
Patent number: 11447537Abstract: The present invention relates to a peptide compound of PDL2 selected from a peptide fragment, a functional homologue, and a functional analogue, as well as to a nucleic acid, such as DNA or RNA, encoding the peptide compound, a vector, such as a virus vector, and a host cell, such as mammalian cell, comprising the vector. The peptide compound, nucleic acid, vector and host cell of the present invention are in particular, useful for the treatment or prevention of a cancer characterized by expression of PDL2.Type: GrantFiled: June 25, 2020Date of Patent: September 20, 2022Assignee: IO BIOTECH APSInventor: Mads Hald Andersen
-
Patent number: 11324813Abstract: The present invention relates to the field of prophylaxis and therapy of cancer. In particular there is provided a protein Indoleamine 2,3-dioxygenase (IDO) or peptide fragments here of that are capable of eliciting anti-cancer immune responses. Specifically, the invention relates to the use of IDO or peptides derived here from or IDO specific T-cells for treatment of cancer. The invention thus relates to an anti-cancer vaccine which optionally may be used in combination with other immunotherapies and to IDO specific T-cells adoptively transferred or induced in vivo by vaccination as a treatment of cancer. It is an aspect of the invention that the medicaments herein provided may be used in combination with cancer chemotherapy treatment. A further aspect relates to the prophylaxis and therapy of infections by the same means as described above. The use of IDO and immunogenic peptide fragments hereof in cancer and infection treatment, diagnosis and prognosis is also provided.Type: GrantFiled: January 29, 2019Date of Patent: May 10, 2022Assignee: IO BIOTECH APSInventors: Mads Hald Andersen, Per Thor Straten
-
Patent number: 11298413Abstract: The present disclosure relates to CCL22 as a novel T cell target in cancer immunosuppression.Type: GrantFiled: September 16, 2016Date of Patent: April 12, 2022Assignee: IO BIOTECH APSInventor: Mads Hald Andersen
-
Patent number: 10858642Abstract: The present invention relates to immunogenic polypeptide fragments of a human Arginase protein. The fragments are in particular useful for the treatment or prevention of cancer.Type: GrantFiled: October 6, 2017Date of Patent: December 8, 2020Assignee: IO Biotech ApSInventor: Mads Hald Andersen
-
Publication number: 20200339659Abstract: The present invention relates to a PD-L1 peptide fragment, useful in cancer therapies as well as PD-L1 peptide fragments for use in a method for treatment or prevention of a cancer, when administered simultaneously or sequentially with an additional cancer therapy.Type: ApplicationFiled: June 20, 2017Publication date: October 29, 2020Applicant: IO Biotech ApSInventor: Mads Hald ANDERSEN
-
Patent number: 10258678Abstract: The present invention relates to the field of prophylaxis and therapy of cancer. In particular there is provided a protein Indoleamine 2,3-dioxygenase (IDO) or peptide fragments here of that are capable of eliciting anti-cancer immune responses. Specifically, the invention relates to the use of IDO or peptides derived here from or IDO specific T-cells for treatment of cancer. The invention thus relates to an anti-cancer vaccine which optionally may be used in combination with other immunotherapies and to IDO specific T-cells adoptively transferred or induced in vivo by vaccination as a treatment of cancer. It is an aspect of the invention that the medicaments herein provided may be used in combination with cancer chemotherapy treatment. A further aspect relates to the prophylaxis and therapy of infections by the same means as described above. The use of IDO and immunogenic peptide fragments hereof in cancer and infection treatment, diagnosis and prognosis is also provided.Type: GrantFiled: August 8, 2016Date of Patent: April 16, 2019Assignee: IO Biotech ApSInventors: Mads Hald Andersen, Per Thor Straten